Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Marstacimab Prophylaxis in Pediatric Hemophilia A and B
NCT05611801Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Dec 2022
- Primary completion
- Sep 2028
- Modality
- Monoclonal Antibodies
- Countries
- 23
01
Overview
Phase 3, open-label, single-arm trial of marstacimab in hemophilia A and hemophilia B (HB), sponsored by Pfizer. Primary endpoints: Annualized bleeding rate of treated bleeding events at 12 months, Incidence of adverse events and serious adverse events at 14 months and 6 more. Started Dec 2022; status: recruiting.
02
Drugs
marstacimab
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT05611801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05611801.